Dogwood Therapeutics, Inc.

  • About
    • Corporate Profile
    • Leadership
    • Board of Directors
    • Corporate Presentation
  • Technology
    • NaV 1.7
    • Antiviral Combination
  • Diseases
    • CINP
    • Long Covid
    • Fibromyalgia
  • Pipeline
  • Clinical Trials
    • CINP 203
  • Investors
  • News

Presentations

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • Events & Presentations

  • Events
  • Presentations
  • Shareholder Letters
  • Meeting
Corporate Presentation
Apr 2, 2025

Corporate Presentation

FORTRESS Study Summary
Sep 19, 2022

FORTRESS Study Summary

International Association for the Study of Pain (IASP) World Congress 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – The Safety of IMC‑1 in Patients With Fibromyalgia: Phase 2a Study Results

International Association for the Study of Pain (IASP) World Congress 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – The Safety of IMC‑1 in Patients With Fibromyalgia: Phase 2a Study Results

EULAR European Congress of Rheumatology 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – IMC‑1, a Fixed Dose Combination of Famciclovir and Celecoxib, Improves Common Symptoms Associated With Fibromyalgia in Addition to Pain: Post Hoc Analysis of a Phase 2a Trial

EULAR European Congress of Rheumatology 2021 Poster Presentation - William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – IMC‑1, a Fixed Dose Combination of Famciclovir and Celecoxib, Improves Common Symptoms Associated With Fibromyalgia in Addition to Pain: Post Hoc Analysis of a Phase 2a Trial

Digestive Disease Week® (DDW) 2021 Presentation – Carol Duffy, PhD; William Pridgen, MD – Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study

Digestive Disease Week® (DDW) 2021 Presentation – Carol Duffy, PhD; William Pridgen, MD – Active Herpes Simplex Virus Type 1 Infection of the Gastric Mucosa is Associated with Functional Gastrointestinal Disorders: A Pilot Case-Control Study

Journal of Pain Research – William Pridgen, MD; Carol Duffy, PhD; Judy F. Gendreau, MD; R. Michael Gendreau, MD, PhD – A Famciclovir + Celecoxib Combination Treatment is Safe and Efficacious in the Treatment of Fibromyalgia

RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2025 Dogwood Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines